50% off Premium Yearly
Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.
Stock price when the opinion was issued
As of Oct 16, 2026. Market Open.
Spun off from Merck two years, but has been sitting in the penalty box. Pays a 5.5% dividend at 5x earnings.
It has no growth.
Build your watch list
Sign in to track investmentsyou care about
Capital Wealth Planning
Capital Area Planning Group
New Edge Capital
Odyssey Capital Advisors
RN Croft Financial Group
Recently on a downward trend. Fundamentally scores 3/10. Would not recommend buying. Price target falling. Has not been able to beat earnings. Better options available for investors. High debt levels not good for dividend outlook.